Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Free Cash Flow: 2019-2024

Historic Free Cash Flow for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to -$44.9 million.

  • Compass Therapeutics' Free Cash Flow rose 2.15% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.1 million, marking a year-over-year increase of 6.29%. This contributed to the annual value of -$44.9 million for FY2024, which is 10.46% down from last year.
  • According to the latest figures from FY2024, Compass Therapeutics' Free Cash Flow is -$44.9 million, which was down 10.46% from -$40.6 million recorded in FY2023.
  • Compass Therapeutics' 5-year Free Cash Flow high stood at -$32,106 for FY2020, and its period low was -$44.9 million during FY2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$40.6 million (2023), whereas its average is -$40.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first increased by 21.09% in 2021, then plummeted by 61.71% in 2022.
  • Yearly analysis of 5 years shows Compass Therapeutics' Free Cash Flow stood at -$32,106 in 2020, then climbed by 16.45% to -$26.9 million in 2020, then rose by 21.09% to -$21.2 million in 2021, then crashed by 61.71% to -$34.3 million in 2022, then declined by 18.38% to -$40.6 million in 2023, then declined by 10.46% to -$44.9 million in 2024.